Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Filgotinib Shaping Up To Be Success Story For Gilead and Galapagos

Executive Summary

Impressive Phase II data for Gilead and Galapagos’ filgotinib in psoriatic arthritis and progress into Phase III for ulcerative colitis suggest that the investigational JAK inhibitor could potentially become a market leader in the class for these and other inflammatory indications.

You may also be interested in...



Gilead Hopes Selectivity Will Ease Safety Labeling For Filgotinib

On pace to file selective JAK1 inhibitor filgotinib for US approval in RA by year’s end, Gilead says the drug’s safety profile may allow for a labeling advantage compared with other drugs in the class.

Galapagos Flies As Filgotinib Soars In FINCH Studies

More evidence of its strong safety profile suggests that the Belgian biotech's oral selective JAK1 inhibitor partnered with Gilead will be able to break into the crowded RA market.

Pharma Q2 Results Preview: Lilly, Biogen, GSK And Gilead

Key strategy updates are coming: GSK will unveil its new R&D approach, Biogen will update investors on its Alzheimer's plans, and investors are keen to find out whether or not Lilly will sell its animal health franchise. Investors will also be keeping an eye on how Gilead is faring with its move into oncology. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel